News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

July 18, 2023

San Francisco Business Times

Read Now
News

Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond

July 18, 2023

Fierce Biotech

Read Now
News

Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

July 18, 2023

STAT News

Read Now
News

Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact

July 17, 2023

Endpoints News

Read Now
News

Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD

July 17, 2023

BioCentury

Read Now
News

Sanofi goes back to Scribe

July 17, 2023

Evaluate

Read Now
Press release

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

February 17, 2026

Read Now
Press release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now
Press release

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now
Press release

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Read Now
Press release

Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences

September 9, 2025

Read Now
Press release

Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences

August 25, 2025

Read Now

Publications and presentations